Publications by authors named "T Lesimple"

Claim this Profile
C
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Thierry Lesimple

Lancet Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study.
M Amici, E Neveu, F Poizeau, J Edeline, T Lesimple

Ann Dermatol Venereol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.
Karine Billard, Laurent Mortier, Olivier Dereure, Sophie Dalac, Henri Montaudié, Thierry Lesimple

Br J Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
Camille Macaire, Wendy Lefevre, Sophie Dalac, Henri Montaudié, Delphine Legoupil, Thierry Lesimple

Melanoma Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When to stop immunotherapy for advanced melanoma: the emulated target trials.
Mathilde Amiot, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sophie Dalac, Thierry Lesimple

EClinicalMedicine· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis